| P50 | author | Antonio Mas | Q45634126 |
| | Francisco Jose Cimas | Q56953554 |
| | Félix A. Jalón | Q60632546 |
| P2093 | author name string | Aimé Vazquez | |
| | Jesús García-Cano | |
| | Leticia Serrano-Oviedo | |
| | Ricardo Sánchez-Prieto | |
| | Gorbatchev Ambroise | |
| | María José Ruiz-Hidalgo | |
| | Isabel Sanchez Perez | |
| | Maria Carmen Carrión | |
| | Marta Ortega-Muelas | |
| | Raquel Pascual-Serra | |
| | Sebastià Sabater | |
| P2860 | cites work | Guidelines for the use and interpretation of assays for monitoring autophagy | Q21996341 |
| | Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC | Q28478252 |
| | BH3-mimetics- and cisplatin-induced cell death proceeds through different pathways depending on the availability of death-related cellular components | Q28486502 |
| | Upregulation of autophagy-related gene-5 (ATG-5) is associated with chemoresistance in human gastric cancer | Q28543901 |
| | Requirement for p53 and p21 to sustain G2 arrest after DNA damage | Q29547667 |
| | Cisplatin: mode of cytotoxic action and molecular basis of resistance | Q29615385 |
| | Identification of a novel inhibitor of mitogen-activated protein kinase kinase | Q29616448 |
| | ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor | Q29616727 |
| | 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes | Q29617843 |
| | Tumour heterogeneity and cancer cell plasticity | Q29617990 |
| | Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy | Q30513775 |
| | Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53. | Q33224549 |
| | Autophagy and cancer therapy | Q33584607 |
| | Synergistic killing of lung cancer cells by cisplatin and radiation via autophagy and apoptosis | Q33727550 |
| | Role of autophagy in cisplatin resistance in ovarian cancer cells | Q33761338 |
| | Concomitant inhibition of AKT and autophagy is required for efficient cisplatin-induced apoptosis of metastatic skin carcinoma. | Q33829753 |
| | Cytotoxic autophagy in cancer therapy | Q33907663 |
| | Phytochemicals: a multitargeted approach to gynecologic cancer therapy. | Q33908881 |
| | Detouring of cisplatin to access mitochondrial genome for overcoming resistance | Q33972195 |
| | Abrogation of the p38 MAPK α signaling pathway does not promote radioresistance but its activity is required for 5-Fluorouracil-associated radiosensitivity. | Q39195786 |
| | Suppression of basal autophagy reduces lung cancer cell proliferation and enhances caspase-dependent and -independent apoptosis by stimulating ROS formation | Q39353049 |
| | P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance | Q39490275 |
| | Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis | Q39520993 |
| | Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy | Q39734588 |
| | Poly(ADPR)polymerase inhibition and apoptosis induction in cDDP-treated human carcinoma cell lines | Q39983946 |
| | Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy | Q40006232 |
| | Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin | Q40195778 |
| | BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. | Q40448987 |
| | Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo | Q40749276 |
| | Requirement for ERK activation in cisplatin-induced apoptosis | Q40854460 |
| | Inhibition of autophagy enhances cisplatin cytotoxicity through endoplasmic reticulum stress in human cervical cancer cells | Q41931397 |
| | Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics | Q41933492 |
| | Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. | Q42442790 |
| | 3-Methyladenine induces cell death and its interaction with chemotherapeutic drugs is independent of autophagy | Q42520512 |
| | A role for the p38 mitogen-acitvated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents | Q42801995 |
| | TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. | Q43202682 |
| | Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties | Q44483506 |
| | Role of the p38 MAPK pathway in cisplatin-based therapy | Q44488190 |
| | Monofunctional platinum complexes showing potent cytotoxicity against human liver carcinoma cell line BEL-7402. | Q44523317 |
| | Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. | Q46601653 |
| | Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance | Q53304624 |
| | Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer | Q54159355 |
| | Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes | Q58283085 |
| | Cisplatin in cancer therapy: molecular mechanisms of action | Q34098163 |
| | Long-term cisplatin exposure impairs autophagy and causes cisplatin resistance in human lung cancer cells | Q34141265 |
| | Synthetic lethality: General principles, utility and detection using genetic screens in human cells | Q34151015 |
| | Tailoring mTOR-based therapy: molecular evidence and clinical challenges | Q34294170 |
| | Induction of autophagy contributes to cisplatin resistance in human ovarian cancer cells | Q34540874 |
| | Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells | Q34603025 |
| | eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206. | Q35534450 |
| | NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response | Q35745292 |
| | Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence | Q36020559 |
| | Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models | Q36552134 |
| | Autophagy in cancer: good, bad, or both? | Q36612549 |
| | Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma | Q36725301 |
| | Novel monofunctional platinum (II) complex Mono-Pt induces apoptosis-independent autophagic cell death in human ovarian carcinoma cells, distinct from cisplatin | Q37043064 |
| | Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. | Q37073574 |
| | Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK. | Q37342850 |
| | Protective effect of metalloporphyrins against cisplatin-induced kidney injury in mice | Q37479069 |
| | Targeting cancer cells through autophagy for anticancer therapy | Q37670439 |
| | The protein disulfide isomerases PDIA4 and PDIA6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma | Q37689423 |
| | Molecular mechanisms of cisplatin resistance | Q37926477 |
| | Chloroquine in cancer therapy: a double-edged sword of autophagy. | Q38071618 |
| | Autophagy and cell death to target cancer cells: exploiting synthetic lethality as cancer therapies | Q38165840 |
| | The machinery of macroautophagy | Q38173673 |
| | The four faces of autophagy: implications for cancer therapy | Q38181453 |
| | Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma | Q38230994 |
| | Synthetic lethal vulnerabilities of cancer | Q38262217 |
| | Applying synthetic lethality for the selective targeting of cancer. | Q38263612 |
| | The role of DNA repair pathways in cisplatin resistant lung cancer | Q38280128 |
| | HMGB1 promotes drug resistance in osteosarcoma | Q38330106 |
| | A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo | Q38411451 |
| | Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance | Q38955141 |
| | MCL-1 dependency of cisplatin-resistant cancer cells | Q38967669 |
| | Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition. | Q38992228 |
| | miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells | Q39039757 |
| | Autophagy inhibition sensitizes cisplatin cytotoxicity in human gastric cancer cell line SGC7901. | Q39089314 |
| | Cisplatin-induced downregulation of SOX1 increases drug resistance by activating autophagy in non-small cell lung cancer cell | Q39101898 |
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autophagy | Q288322 |
| | cisplatin | Q412415 |
| P1104 | number of pages | 15 | |
| P304 | page(s) | 15551-15565 | |
| P577 | publication date | 2015-06-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance | |
| P478 | volume | 6 | |